Skip to content
Privacy Policy

A subsidiary of TransCelerate BioPharma Inc.

Welcome to BioCelerate

BioCelerate, a subsidiary of TransCelerate BioPharma Inc., focuses on the identification and development of pragmatic and tangible solutions to improve efficiencies in nonclinical research, with the end goal of improving overall drug development efficiency to bring new medicines to patients faster. By actively collaborating with participating TransCelerate Member Companies and other industry stakeholders, BioCelerate leverages collective knowledge to tackle areas of common challenge and unmet need in the nonclinical research space.

Meet the

BioCelerate Members

The initial biopharmaceutical companies committed to launching BioCelerate include Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Novo Nordisk and Shionogi & Co., Ltd.

BMS Logo
Pfizer - Member of TransCelerate BioPharma Inc.

About the

Leadership & Governing Model

BioCelerate is led by the Chief Executive Officer of TransCelerate, Dalvir Gill, PhD. For more on Dr. Gill, please see his bio on the TransCelerate leadership page. BioCelerate is a subsidiary of TransCelerate BioPharma, and draws upon separate funding and support. In order to participate in BioCelerate it is necessary to be a Member Company of TransCelerate BioPharma, Inc. TransCelerate membership is available to biopharmaceutical research and development organizations who engage in innovative discovery, development and manufacturing of new drugs. Information about membership and a membership application is available on the TransCelerate website. BioCelerate initiatives are approved by a Governing Council comprised of representatives from participating BioCelerate Companies.

Translate »